All In Biotech

Drug Trial Radar · NCT00889954

Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy

Administration of Her2 Chimeric Receptor and TGFbeta Dominant Negative Receptor (DNR) Expressing EBV Specific Lymphocytes for Subjects With Advanced Her2 Positive Malignancy (HERCREEM)

Last checked: Nov 19, 2026Latest source record: Sep 18, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

May 2009

Primary completion

Jul 2015

Study completion Jan 21, 2018

Sponsor

Lead sponsor
Baylor College of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy, Baylor College of Medicine
First posted
Apr 29, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients have advanced stage cancer. This study is a gene transfer research study using special immune cells. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Investigators hope that both will work better together. Antibodies are proteins that protect the body from diseases caused from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected with germs. Both antibodies and T cells have been used to treat patients with cancers: they both have shown promise, but have not been strong enough to cure most patients. T lymphocytes can kill tumor cells but there are normally not enough of them or they are not able to kill all the tumor cells. We have done research in which we have grown "extra" T lymphocytes. We have added genes to those T lymphocytes to help them to recognize tumor cells. Although the results have been promising, we are still doing more research in this area. Antibodies usually circulate in blood and are secreted by other cells of the immune system in response to the presence of germs or abnormal cells in the body. The antibody used in this study is called anti-HER2 (Human Epidermal Growth Factor Receptor 2). This antibody sticks to HER2-positive cancer cells because of a substance on the outside of these cells called HER2.

Conditions

  • HER2 Positive Malignancies

Interventions

  • TGFBeta resistant HER2/EBV-CTLsBiological

    Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT). Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients with dose limiting toxicity.Time frame: 6 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Houston Methodist Hospital

    Houston, Texas

  • Texas Children's Hospital

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.